
1.
Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB/c mice.
Jiang Y, Zhu Y, Mu Q, Luo H, Zhi Y, Shen X.
Antiviral Res. 2017 Jan 20. pii: S0166-3542(16)30524-1. doi: 10.1016/j.antiviral.2017.01.013. [Epub ahead of print]
PMID: 28115196
Similar articles
Select item 28109912
2.
IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha.
Li L, Fu F, Xue M, Chen W, Liu J, Shi H, Chen J, Bu Z, Feng L, Liu P.
Antiviral Res. 2017 Jan 18. pii: S0166-3542(16)30299-6. doi: 10.1016/j.antiviral.2017.01.012. [Epub ahead of print]
PMID: 28109912
Similar articles
Select item 28093339
3.
Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Chittick G, Morrison M, Brundage T, Nichols WG.
Antiviral Res. 2017 Jan 13. pii: S0166-3542(16)30714-8. doi: 10.1016/j.antiviral.2017.01.009. [Epub ahead of print]
PMID: 28093339
Similar articles
Select item 28093338
4.
A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR, Cheng CY, Chen CY, Lin CH, Kuo CY, Huang HY, Wu FT, Yang YC, Wu CY, Liu MT, Hsiao PW.
Antiviral Res. 2017 Jan 13. pii: S0166-3542(16)30621-0. doi: 10.1016/j.antiviral.2017.01.010. [Epub ahead of print]
PMID: 28093338
Similar articles
Select item 28093337
5.
NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection.
de Groen RA, Hou J, van Oord GW, Groothuismink ZM, van der Heide M, de Knegt RJ, Boonstra A.
Antiviral Res. 2017 Jan 14;140:18-24. doi: 10.1016/j.antiviral.2017.01.007. [Epub ahead of print]
PMID: 28093337 Free Article
Similar articles
Select item 28088354
6.
Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.
Albulescu L, Bigay J, Biswas B, Weber-Boyvat M, Dorobantu CM, Delang L, van der Schaar HM, Jung YS, Neyts J, Olkkonen VM, van Kuppeveld FJ, Strating JR.
Antiviral Res. 2017 Jan 11;140:37-44. doi: 10.1016/j.antiviral.2017.01.008. [Epub ahead of print]
PMID: 28088354 Free Article
Similar articles
Select item 28087313
7.
An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y, Musharrafieh R, Ma C, Zhang J, Smee DF, DeGrado WF, Wang J.
Antiviral Res. 2017 Jan 10;140:45-54. doi: 10.1016/j.antiviral.2017.01.006. [Epub ahead of print]
PMID: 28087313
Similar articles
Select item 28077314
8.
Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.
Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, Herrera Carrillo E, Brandsma JH, Poot RA, Berkhout B, Neyts J, Peppelenbosch MP, Pan Q.
Antiviral Res. 2017 Jan 8;140:1-12. doi: 10.1016/j.antiviral.2017.01.005. [Epub ahead of print]
PMID: 28077314
Similar articles
Select item 28063996
9.
Porcine parvovirus capsid protein expressed in Escherichia coli self-assembles into virus-like particles with high immunogenicity in mice and guinea pigs.
Ji P, Liu Y, Chen Y, Wang A, Jiang D, Zhao B, Wang J, Chai S, Zhou E, Zhang G.
Antiviral Res. 2017 Jan 4;139:146-152. doi: 10.1016/j.antiviral.2017.01.003. [Epub ahead of print]
PMID: 28063996
Similar articles
Select item 28063995
10.
Activation of TNF-α-AID axis and co-inhibitory signals in coordination with Th1-type immunity in a mouse model recapitulating hepatitis B.
Matsumoto T, Takahashi K, Inuzuka T, Kim SK, Kurosaki T, Kawakami S, Chiba T, Seno H, Marusawa H.
Antiviral Res. 2017 Jan 5;139:138-145. doi: 10.1016/j.antiviral.2017.01.004. [Epub ahead of print]
PMID: 28063995
Similar articles
Select item 28063994
11.
Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells.
Ghezzi S, Cooper L, Rubio A, Pagani I, Capobianchi MR, Ippolito G, Pelletier J, Meneghetti MC, Lima MA, Skidmore MA, Broccoli V, Yates EA, Vicenzi E.
Antiviral Res. 2017 Jan 5;140:13-17. doi: 10.1016/j.antiviral.2016.12.023. [Epub ahead of print]
PMID: 28063994
Similar articles
Select item 28063993
12.
Inhibition of enterovirus 71 replication by an α-hydroxy-nitrile derivative NK-1.9k.
Wang Y, Cao L, Zhai Y, Ma J, Nie Q, Li T, Yin Z, Sun Y, Shang L.
Antiviral Res. 2017 Jan 4. pii: S0166-3542(16)30564-2. doi: 10.1016/j.antiviral.2017.01.002. [Epub ahead of print]
PMID: 28063993
Similar articles
Select item 28062191
13.
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ.
Antiviral Res. 2017 Jan 3;139:129-137. doi: 10.1016/j.antiviral.2017.01.001. [Epub ahead of print]
PMID: 28062191
Similar articles
Select item 28049006
14.
Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism.
Kuivanen S, Bespalov MM, Nandania J, Ianevski A, Velagapudi V, De Brabander JK, Kainov DE, Vapalahti O.
Antiviral Res. 2016 Dec 31;139:117-128. doi: 10.1016/j.antiviral.2016.12.022. [Epub ahead of print]
PMID: 28049006
Similar articles
Select item 28041959
15.
Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2'-modified nucleotide analogues.
Potisopon S, Ferron F, Fattorini V, Selisko B, Canard B.
Antiviral Res. 2016 Dec 30;140:25-36. doi: 10.1016/j.antiviral.2016.12.021. [Epub ahead of print]
PMID: 28041959
Similar articles
Select item 28040513
16.
Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice.
Wang C, Zheng X, Gai W, Wong G, Wang H, Jin H, Feng N, Zhao Y, Zhang W, Li N, Zhao G, Li J, Yan J, Gao Y, Hu G, Yang S, Xia X.
Antiviral Res. 2016 Dec 28. pii: S0166-3542(16)30393-X. doi: 10.1016/j.antiviral.2016.12.019. [Epub ahead of print]
PMID: 28040513
Similar articles
Select item 28039021
17.
Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R, Korom M, Buller RM, Parker S.
Antiviral Res. 2016 Dec 27;139:112-116. doi: 10.1016/j.antiviral.2016.12.015. [Epub ahead of print]
PMID: 28039021
Similar articles
Select item 28039020
18.
Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.
Abdelnabi R, Amrun SN, Ng LF, Leyssen P, Neyts J, Delang L.
Antiviral Res. 2016 Dec 27;139:79-87. doi: 10.1016/j.antiviral.2016.12.020. [Epub ahead of print]
PMID: 28039020
Similar articles
Select item 28034744
19.
Extended substrate specificity and first potent irreversible inhibitor/activity-based probe design for Zika virus NS2B-NS3 protease.
Rut W, Zhang L, Kasperkiewicz P, Poreba M, Hilgenfeld R, Drąg M.
Antiviral Res. 2016 Dec 26;139:88-94. doi: 10.1016/j.antiviral.2016.12.018. [Epub ahead of print]
PMID: 28034744
Similar articles
Select item 28034743
20.
Discovery of host-targeted covalent inhibitors of dengue virus.
de Wispelaere M, Carocci M, Liang Y, Liu Q, Sun E, Vetter ML, Wang J, Gray NS, Yang PL.
Antiviral Res. 2016 Dec 26;139:171-179. doi: 10.1016/j.antiviral.2016.12.017. [Epub ahead of print]
PMID: 28034743
Similar articles
Select item 28034742
21.
Activity of andrographolide against dengue virus.
Panraksa P, Ramphan S, Khongwichit S, Smith DR.
Antiviral Res. 2016 Dec 26;139:69-78. doi: 10.1016/j.antiviral.2016.12.014. [Epub ahead of print]
PMID: 28034742
Similar articles
Select item 28034741
22.
Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus.
Lee H, Ren J, Nocadello S, Rice AJ, Ojeda I, Light S, Minasov G, Vargas J, Nagarathnam D, Anderson WF, Johnson ME.
Antiviral Res. 2016 Dec 26;139:49-58. doi: 10.1016/j.antiviral.2016.12.016. [Epub ahead of print]
PMID: 28034741
Similar articles
Select item 28027917
23.
Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, Okuda T, Shiraki K.
Antiviral Res. 2016 Dec 24;139:95-101. doi: 10.1016/j.antiviral.2016.12.008. [Epub ahead of print]
PMID: 28027917
Similar articles
Select item 28025085
24.
Modelling viral infections using zebrafish: Innate immune response and antiviral research.
Varela M, Figueras A, Novoa B.
Antiviral Res. 2016 Dec 23;139:59-68. doi: 10.1016/j.antiviral.2016.12.013. [Epub ahead of print] Review.
PMID: 28025085
Similar articles
Select item 28025084
25.
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Tao W, Gan T, Lu J, Zhong J.
Antiviral Res. 2016 Dec 23;139:18-24. doi: 10.1016/j.antiviral.2016.12.009. [Epub ahead of print]
PMID: 28025084
Similar articles
Select item 28017762
26.
Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid.
Martínez-Gualda B, Sun L, Rivero-Buceta E, Flores A, Quesada E, Balzarini J, Noppen S, Liekens S, Schols D, Neyts J, Leyssen P, Mirabelli C, Camarasa MJ, San-Félix A.
Antiviral Res. 2016 Dec 23;139:32-40. doi: 10.1016/j.antiviral.2016.12.010. [Epub ahead of print]
PMID: 28017762 Free Article
Similar articles
Select item 28017761
27.
Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
Liu Y, Miller MD, Kitrinos KM.
Antiviral Res. 2016 Dec 23;139:25-31. doi: 10.1016/j.antiviral.2016.12.012. [Epub ahead of print]
PMID: 28017761
Similar articles
Select item 28012921
28.
Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Kobayashi M, Kodama M, Noshi T, Yoshida R, Kanazu T, Nomura N, Soda K, Isoda N, Okamatsu M, Sakoda Y, Yamano Y, Sato A, Kida H.
Antiviral Res. 2016 Dec 22;139:41-48. doi: 10.1016/j.antiviral.2016.12.011. [Epub ahead of print]
PMID: 28012921
Similar articles
Select item 27984060
29.
Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A, Obaid A, Awan FM, Hanif R, Naz A, Paracha RZ, Ali A, Janjua HA.
Antiviral Res. 2017 Jan;137:112-124. doi: 10.1016/j.antiviral.2016.10.013.
PMID: 27984060
Similar articles
Select item 27956136
30.
Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model.
Kumaki Y, Salazar AM, Wandersee MK, Barnard DL.
Antiviral Res. 2016 Dec 9;139:1-12. doi: 10.1016/j.antiviral.2016.12.007. [Epub ahead of print]
PMID: 27956136
Similar articles
Select item 27956135
31.
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ.
Antiviral Res. 2017 Feb;138:79-85. doi: 10.1016/j.antiviral.2016.12.005.
PMID: 27956135
Similar articles
Select item 27956134
32.
Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins.
Beelontally R, Wilkie GS, Lau B, Goodmaker CJ, Ho CM, Swanson CM, Deng X, Wang J, Gray NS, Davison AJ, Strang BL.
Antiviral Res. 2017 Feb;138:61-67. doi: 10.1016/j.antiviral.2016.12.006.
PMID: 27956134 Free Article
Similar articles
Select item 27940027
33.
Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S.
Antiviral Res. 2017 Feb;138:57-60. doi: 10.1016/j.antiviral.2016.12.003.
PMID: 27940027
Similar articles
Select item 27939841
34.
Meeting report: Third Summer School on Innovative Approaches for Identification of Antiviral Agents (IAAASS).
Le Grice SF, Sztuba-Solinska J, Maccioni E, Purzycka KJ, Parolin C, Tramontano E.
Antiviral Res. 2016 Dec 8;139:13-17. doi: 10.1016/j.antiviral.2016.12.004. [Epub ahead of print] Review.
PMID: 27939841
Similar articles
Select item 27939840
35.
Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
Huang L, Yang M, Yuan Y, Li X, Kuang E.
Antiviral Res. 2017 Feb;138:68-78. doi: 10.1016/j.antiviral.2016.12.002.
PMID: 27939840
Similar articles
Select item 27923570
36.
Recombinant DNA vaccine of Hantavirus Gn and LAMP1 induced long-term immune protection in mice.
Jiang DB, Sun LJ, Cheng LF, Zhang JP, Xiao SB, Sun YJ, Yang SY, Wang J, Zhang FL, Yang K.
Antiviral Res. 2017 Feb;138:32-39. doi: 10.1016/j.antiviral.2016.12.001.
PMID: 27923570
Similar articles
Select item 27919709
37.
Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay.
Adcock RS, Chu YK, Golden JE, Chung DH.
Antiviral Res. 2017 Feb;138:47-56. doi: 10.1016/j.antiviral.2016.11.018.
PMID: 27919709
Similar articles
Select item 27914937
38.
Mcl-1 small-molecule inhibitors encapsulated into nanoparticles exhibit increased killing efficacy towards HCMV-infected monocytes.
Burrer CM, Auburn H, Wang X, Luo J, Abulwerdi FA, Nikolovska-Coleska Z, Chan GC.
Antiviral Res. 2017 Feb;138:40-46. doi: 10.1016/j.antiviral.2016.11.027.
PMID: 27914937
Similar articles
Select item 27908832
39.
Evaluation of two strains of Marek's disease virus serotype 1 for the development of recombinant vaccines against very virulent infectious bursal disease virus.
Li K, Liu Y, Liu C, Gao L, Gao Y, Zhang Y, Cui H, Qi X, Zhong L, Wang X.
Antiviral Res. 2016 Nov 28;139:153-160. doi: 10.1016/j.antiviral.2016.11.024. [Epub ahead of print]
PMID: 27908832
Similar articles
Select item 27908831
40.
Eukaryotic translational initiation factor 4AII reduces the replication of infectious bursal disease virus by inhibiting VP1 polymerase activity.
Gao L, Li K, Zhong L, Zhang L, Qi X, Wang Y, Gao Y, Wang X.
Antiviral Res. 2016 Nov 28;139:102-111. doi: 10.1016/j.antiviral.2016.11.022. [Epub ahead of print]
PMID: 27908831
Similar articles
Select item 27908830
41.
Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
Yang WT, Yang GL, Wang Q, Huang HB, Jiang YL, Shi CW, Wang JZ, Huang KY, Jin YB, Wang CF.
Antiviral Res. 2017 Feb;138:9-21. doi: 10.1016/j.antiviral.2016.11.025.
PMID: 27908830
Similar articles
Select item 27908829
42.
Exploring the binding mechanism of Heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics.
Tu J, Li JJ, Shan ZJ, Zhai HL.
Antiviral Res. 2017 Jan;137:151-164. doi: 10.1016/j.antiviral.2016.11.026.
PMID: 27908829
Similar articles
Select item 27908828
43.
Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.
Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.
Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019.
PMID: 27908828
Similar articles
Select item 27908827
44.
Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3.
Sánchez-Cordón PJ, Chapman D, Jabbar T, Reis AL, Goatley L, Netherton CL, Taylor G, Montoya M, Dixon L.
Antiviral Res. 2017 Feb;138:1-8. doi: 10.1016/j.antiviral.2016.11.021.
PMID: 27908827 Free Article
Similar articles
Select item 27902933
45.
The FDA-approved drug sofosbuvir inhibits Zika virus infection.
Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, Geiss BJ.
Antiviral Res. 2017 Jan;137:134-140. doi: 10.1016/j.antiviral.2016.11.023.
PMID: 27902933
Similar articles
Select item 27902932
46.
Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase.
Hercík K, Kozak J, Šála M, Dejmek M, Hřebabecký H, Zborníková E, Smola M, Ruzek D, Nencka R, Boura E.
Antiviral Res. 2017 Jan;137:131-133. doi: 10.1016/j.antiviral.2016.11.020.
PMID: 27902932
Similar articles
Select item 27890675
47.
Synergistic drug combination effectively blocks Ebola virus infection.
Sun W, He S, Martínez-Romero C, Kouznetsova J, Tawa G, Xu M, Shinn P, Fisher EG, Long Y, Motabar O, Yang S, Sanderson PE, Williamson PR, García-Sastre A, Qiu X, Zheng W.
Antiviral Res. 2017 Jan;137:165-172. doi: 10.1016/j.antiviral.2016.11.017.
PMID: 27890675 Free Article
Similar articles
Select item 27890674
48.
Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model.
Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F, Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, Xia X.
Antiviral Res. 2017 Jan;137:125-130. doi: 10.1016/j.antiviral.2016.11.016.
PMID: 27890674
Similar articles
Select item 27889530
49.
Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.
Vemula SV, Maxwell JW, Nefedov A, Wan BL, Steve J, Newhard W, Sanchez RI, Tellers D, Barnard RJ, Blair W, Hazuda D, Webber AL, Howell BJ.
Antiviral Res. 2016 Nov 23;139:161-170. doi: 10.1016/j.antiviral.2016.11.014. [Epub ahead of print]
PMID: 27889530
Similar articles
Select item 27889529
50.
Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus.
Balasubramanian A, Teramoto T, Kulkarni AA, Bhattacharjee AK, Padmanabhan R.
Antiviral Res. 2017 Jan;137:141-150. doi: 10.1016/j.antiviral.2016.11.015.
PMID: 27889529
Similar articles
Select item 27887982
51.
Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
Campos AB, Ribeiro J, Pinho Vaz C, Campilho F, Branca R, Campos A Jr, Baldaque I, Medeiros R, Boutolleau D, Sousa H.
Antiviral Res. 2017 Feb;138:86-92. doi: 10.1016/j.antiviral.2016.10.016.
PMID: 27887982
Similar articles
Select item 27876497
52.
Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7.
Mele D, Mantovani S, Oliviero B, Grossi G, Ludovisi S, Mondelli MU, Varchetta S.
Antiviral Res. 2017 Jan;137:108-111. doi: 10.1016/j.antiviral.2016.11.013.
PMID: 27876497
Similar articles
Select item 27871886
53.
Tetrahalogenated benzimidazole D-ribonucleosides are active against rat cytomegalovirus.
Dittmer A, Woskobojnik I, Adfeldt R, Drach JC, Townsend LB, Voigt S, Bogner E.
Antiviral Res. 2017 Jan;137:102-107. doi: 10.1016/j.antiviral.2016.11.012.
PMID: 27871886
Similar articles
Select item 27864075
54.
The natural compound silvestrol is a potent inhibitor of Ebola virus replication.
Biedenkopf N, Lange-Grünweller K, Schulte FW, Weißer A, Müller C, Becker D, Becker S, Hartmann RK, Grünweller A.
Antiviral Res. 2017 Jan;137:76-81. doi: 10.1016/j.antiviral.2016.11.011.
PMID: 27864075
Similar articles
Select item 27864074
55.
Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y, Ma S, Zhu L, Huang Z, Chen L, Xu Y, Yin H, Peng T, Wang Y.
Antiviral Res. 2017 Jan;137:67-75. doi: 10.1016/j.antiviral.2016.11.008.
PMID: 27864074
Similar articles
Select item 27847245
56.
Celastrol inhibits dengue virus replication via up-regulating type I interferon and downstream interferon-stimulated responses.
Yu JS, Tseng CK, Lin CK, Hsu YC, Wu YH, Hsieh CL, Lee JC.
Antiviral Res. 2017 Jan;137:49-57. doi: 10.1016/j.antiviral.2016.11.010.
PMID: 27847245
Similar articles
Select item 27840203
57.
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.
Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF.
Antiviral Res. 2017 Jan;137:82-92. doi: 10.1016/j.antiviral.2016.11.006. Review.
PMID: 27840203
Similar articles
Select item 27840202
58.
Reducing the global burden of HTLV-1 infection: An agenda for research and action.
Willems L, Hasegawa H, Accolla R, Bangham C, Bazarbachi A, Bertazzoni U, Carneiro-Proietti AB, Cheng H, Chieco-Bianchi L, Ciminale V, Coelho-Dos-Reis J, Esparza J, Gallo RC, Gessain A, Gotuzzo E, Hall W, Harford J, Hermine O, Jacobson S, Macchi B, Macpherson C, Mahieux R, Matsuoka M, Murphy E, Peloponese JM, Simon V, Tagaya Y, Taylor GP, Watanabe T, Yamano Y.
Antiviral Res. 2017 Jan;137:41-48. doi: 10.1016/j.antiviral.2016.10.015. Review.
PMID: 27840202
Similar articles
Select item 27840201
59.
Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface.
Yuan S, Chu H, Ye J, Singh K, Ye Z, Zhao H, Kao RY, Chow BK, Zhou J, Zheng BJ.
Antiviral Res. 2017 Jan;137:58-66. doi: 10.1016/j.antiviral.2016.11.005.
PMID: 27840201
Similar articles
Select item 27838352
60.
Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model.
Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, Stewart J, Collins P, Gebre M, Neilson S, Van Wettere A, Lee YM, Sheridan WP, Morrey JD, Babu YS.
Antiviral Res. 2017 Jan;137:14-22. doi: 10.1016/j.antiviral.2016.11.003.
PMID: 27838352
Similar articles
Select item 27838351
61.
The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
Tu V, Abed Y, Barbeau X, Carbonneau J, Fage C, Lagüe P, Boivin G.
Antiviral Res. 2017 Jan;137:6-13. doi: 10.1016/j.antiviral.2016.11.007.
PMID: 27838351
Similar articles
Select item 27838350
62.
Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.
Telcian AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, Mallia P, Johnston SL, Stanciu LA.
Antiviral Res. 2017 Jan;137:93-101. doi: 10.1016/j.antiviral.2016.11.004.
PMID: 27838350
Similar articles
Select item 27832942
63.
Amending Koch's postulates for viral disease: When "growth in pure culture" leads to a loss of virulence.
Prescott J, Feldmann H, Safronetz D.
Antiviral Res. 2017 Jan;137:1-5. doi: 10.1016/j.antiviral.2016.11.002. Review.
PMID: 27832942
Similar articles
Select item 27825797
64.
An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP, Stewart RA, Hogan PA, Ptak RG, Mankowski MK, Hartman TL, Buckheit RW Jr, Snyder BA, Salter JD, Morales GA, Smith HC.
Antiviral Res. 2016 Dec;136:51-59. doi: 10.1016/j.antiviral.2016.11.001.
PMID: 27825797
Similar articles
Select item 27815125
65.
Meeting report: 29th International Conference on Antiviral Research in La Jolla, CA, USA.
Vere Hodge RA.
Antiviral Res. 2017 Jan;137:23-40. doi: 10.1016/j.antiviral.2016.10.014. Review.
PMID: 27815125
Similar articles
Select item 27793564
66.
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A.
Antiviral Res. 2016 Dec;136:32-36. doi: 10.1016/j.antiviral.2016.10.011.
PMID: 27793564
Similar articles
Select item 27789224
67.
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
Ogawa E, Furusyo N, Nomura H, Takahashi K, Higashi N, Kawano A, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..
Antiviral Res. 2016 Dec;136:37-44. doi: 10.1016/j.antiviral.2016.10.012.
PMID: 27789224
Similar articles
Select item 27771388
68.
Intranasal treatment with a novel immunomodulator mediates innate immune protection against lethal pneumonia virus of mice.
Martinez EC, Garg R, Shrivastava P, Gomis S, van Drunen Littel-van den Hurk S.
Antiviral Res. 2016 Nov;135:108-119. doi: 10.1016/j.antiviral.2016.10.008.
PMID: 27771388
Similar articles
Select item 27746249
69.
The SARE tool for rabies control: Current experience in Ethiopia.
Coetzer A, Kidane AH, Bekele M, Hundera AD, Pieracci EG, Shiferaw ML, Wallace R, Nel LH.
Antiviral Res. 2016 Nov;135:74-80. doi: 10.1016/j.antiviral.2016.09.011. Review.
PMID: 27746249
Similar articles
Select item 27743917
70.
Modelling Ebola virus dynamics: Implications for therapy.
Martyushev A, Nakaoka S, Sato K, Noda T, Iwami S.
Antiviral Res. 2016 Nov;135:62-73. doi: 10.1016/j.antiviral.2016.10.004.
PMID: 27743917
Similar articles
Select item 27743916
71.
Bioinformatics and functional analyses of coronavirus nonstructural proteins involved in the formation of replicative organelles.
Neuman BW.
Antiviral Res. 2016 Nov;135:97-107. doi: 10.1016/j.antiviral.2016.10.005. Review.
PMID: 27743916
Similar articles
Select item 27742486
72.
Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission.
Wang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC, Ho YJ.
Antiviral Res. 2016 Nov;135:81-90. doi: 10.1016/j.antiviral.2016.10.003.
PMID: 27742486
Similar articles
Select item 27737787
73.
Ineffectiveness of rabies vaccination alone for post-exposure protection against rabies infection in animal models.
Zhang Y, Zhang S, Li L, Hu R, Lin H, Liu H, Liu F, Shao H, Liu Y.
Antiviral Res. 2016 Nov;135:56-61. doi: 10.1016/j.antiviral.2016.10.002.
PMID: 27737787
Similar articles
Select item 27713074
74.
An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA.
Antiviral Res. 2016 Nov;135:48-55. doi: 10.1016/j.antiviral.2016.10.001.
PMID: 27713074
Similar articles
Select item 27713073
75.
A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus.
Spengler JR, Estrada-Peña A, Garrison AR, Schmaljohn C, Spiropoulou CF, Bergeron É, Bente DA.
Antiviral Res. 2016 Nov;135:31-47. doi: 10.1016/j.antiviral.2016.09.013. Review.
PMID: 27713073
Similar articles
Select item 27693161
76.
Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors.
Lu G, Villa JA, Donlin MJ, Edwards TC, Cheng X, Heier RF, Meyers MJ, Tavis JE.
Antiviral Res. 2016 Nov;135:24-30. doi: 10.1016/j.antiviral.2016.09.009.
PMID: 27693161
Similar articles
Select item 27678155
77.
The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.
Pitt EA, Dogra P, Patel RS, Williams A, Wall JS, Sparer TE.
Antiviral Res. 2016 Nov;135:15-23. doi: 10.1016/j.antiviral.2016.09.012.
PMID: 27678155
Similar articles
Select item 27640102
78.
Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry.
Martin B, Hoenen T, Canard B, Decroly E.
Antiviral Res. 2016 Nov;135:1-14. doi: 10.1016/j.antiviral.2016.09.001. Review.
PMID: 27640102
Similar articles
Select item 27594527
79.
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
El Chaer F, Mori N, Shah D, Oliver N, Wang E, Jan A, Doan V, Tverdek F, Tayar J, Ariza-Heredia E, Chemaly RF.
Antiviral Res. 2016 Nov;135:91-96. doi: 10.1016/j.antiviral.2016.08.027.
PMID: 27594527
Similar articles
Select item 27773751
80.
Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus.
Pinkert S, Dieringer B, Diedrich S, Zeichhardt H, Kurreck J, Fechner H.
Antiviral Res. 2016 Dec;136:1-8. doi: 10.1016/j.antiviral.2016.10.010.
PMID: 27773751
Similar articles
Select item 27771390
81.
Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
Smee DF, Barnard DL, Jones SM.
Antiviral Res. 2016 Dec;136:45-50. doi: 10.1016/j.antiviral.2016.10.009.
PMID: 27771390
Similar articles
Select item 27771389
82.
Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
Welch SR, Guerrero LW, Chakrabarti AK, McMullan LK, Flint M, Bluemling GR, Painter GR, Nichol ST, Spiropoulou CF, Albariño CG.
Antiviral Res. 2016 Dec;136:9-18. doi: 10.1016/j.antiviral.2016.10.007.
PMID: 27771389
Similar articles
Select item 27771387
83.
HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes.
Alfaiate D, Lucifora J, Abeywickrama-Samarakoon N, Michelet M, Testoni B, Cortay JC, Sureau C, Zoulim F, Dény P, Durantel D.
Antiviral Res. 2016 Dec;136:19-31. doi: 10.1016/j.antiviral.2016.10.006.
PMID: 27771387
Similar articles
Select item 27666184
84.
Flavivirus RNA transactions from viral entry to genome replication.
Garcia-Blanco MA, Vasudevan SG, Bradrick SS, Nicchitta C.
Antiviral Res. 2016 Oct;134:244-249. doi: 10.1016/j.antiviral.2016.09.010. Review.
PMID: 27666184
Similar articles
Select item 27659398
85.
New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H.
Corona A, di Leva FS, Rigogliuso G, Pescatori L, Madia VN, Subra F, Delelis O, Esposito F, Cadeddu M, Costi R, Cosconati S, Novellino E, di Santo R, Tramontano E.
Antiviral Res. 2016 Oct;134:236-243. doi: 10.1016/j.antiviral.2016.09.008.
PMID: 27659398
Similar articles
Select item 27649989
86.
Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor.
Tarantino D, Cannalire R, Mastrangelo E, Croci R, Querat G, Barreca ML, Bolognesi M, Manfroni G, Cecchetti V, Milani M.
Antiviral Res. 2016 Oct;134:226-235. doi: 10.1016/j.antiviral.2016.09.007.
PMID: 27649989 Free Article
Similar articles
Select item 27637905
87.
Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity.
Bissa M, Quaglino E, Zanotto C, Illiano E, Rolih V, Pacchioni S, Cavallo F, De Giuli Morghen C, Radaelli A.
Antiviral Res. 2016 Oct;134:182-191. doi: 10.1016/j.antiviral.2016.09.002.
PMID: 27637905
Similar articles
Select item 27633452
88.
Targeting deoxyhypusine hydroxylase activity impairs cap-independent translation initiation driven by the 5'untranslated region of the HIV-1, HTLV-1, and MMTV mRNAs.
Cáceres CJ, Angulo J, Contreras N, Pino K, Vera-Otarola J, López-Lastra M.
Antiviral Res. 2016 Oct;134:192-206. doi: 10.1016/j.antiviral.2016.09.006.
PMID: 27633452
Similar articles
Select item 27623347
89.
Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge.
Sun J, Ennis J, Turner JD, Chu JJ.
Antiviral Res. 2016 Oct;134:207-215. doi: 10.1016/j.antiviral.2016.09.003.
PMID: 27623347
Similar articles
Select item 27623346
90.
The antiviral effect of mollusk mucus on measles virus.
Toledo-Piza AR, Figueiredo CA, Oliveira MI, Negri G, Namiyama G, Tonelotto M, Villar KS, Rofatto HK, Mendonça RZ.
Antiviral Res. 2016 Oct;134:172-181. doi: 10.1016/j.antiviral.2016.09.005.
PMID: 27623346
Similar articles
Select item 27623345
91.
A competitive ELISA for species-independent detection of Crimean-Congo hemorrhagic fever virus specific antibodies.
Schuster I, Mertens M, Köllner B, Korytář T, Keller M, Hammerschmidt B, Müller T, Tordo N, Marianneau P, Mroz C, Rissmann M, Stroh E, Dähnert L, Hammerschmidt F, Ulrich RG, Groschup MH.
Antiviral Res. 2016 Oct;134:161-166. doi: 10.1016/j.antiviral.2016.09.004.
PMID: 27623345
Similar articles
Select item 27591143
92.
Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA.
Liu C, Cai D, Zhang L, Tang W, Yan R, Guo H, Chen X.
Antiviral Res. 2016 Oct;134:97-107. doi: 10.1016/j.antiviral.2016.08.026.
PMID: 27591143
Similar articles
Select item 27591142
93.
Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo.
Li B, Sun S, Li M, Cheng X, Li H, Kang F, Kang J, Dörnbrack K, Nassal M, Sun D.
Antiviral Res. 2016 Oct;134:117-129. doi: 10.1016/j.antiviral.2016.08.007.
PMID: 27591142
Similar articles
Select item 27582067
94.
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
El-Haddad D, El Chaer F, Vanichanan J, Shah DP, Ariza-Heredia EJ, Mulanovich VE, Gulbis AM, Shpall EJ, Chemaly RF.
Antiviral Res. 2016 Oct;134:58-62. doi: 10.1016/j.antiviral.2016.08.024.
PMID: 27582067
Similar articles
Select item 27582066
95.
A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6.
Yang L, Mao Q, Li S, Gao F, Zhao H, Liu Y, Wan J, Ye X, Xia N, Cheng T, Liang Z.
Antiviral Res. 2016 Oct;134:50-57. doi: 10.1016/j.antiviral.2016.08.025.
PMID: 27582066
Similar articles
Select item 27577529
96.
Suramin treatment reduces chikungunya pathogenesis in mice.
Kuo SC, Wang YM, Ho YJ, Chang TY, Lai ZZ, Tsui PY, Wu TY, Lin CC.
Antiviral Res. 2016 Oct;134:89-96. doi: 10.1016/j.antiviral.2016.07.025.
PMID: 27577529 Free Article
Similar articles
Select item 27575793
97.
New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase.
Fearns R, Deval J.
Antiviral Res. 2016 Oct;134:63-76. doi: 10.1016/j.antiviral.2016.08.006. Review.
PMID: 27575793 Free Article
Similar articles
Select item 27568924
98.
Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.
Hartman TL, Yang L, Helfrick AN, Hassink M, Shank NI, George Rosenker K, Scerba MT, Saha M, Hughes E, Wang AQ, Xu X, Gupta P, Buckheit RW Jr, Appella DH.
Antiviral Res. 2016 Oct;134:216-225. doi: 10.1016/j.antiviral.2016.08.022.
PMID: 27568924
Similar articles
Select item 27568923
99.
Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.
Yates PJ, Raimonde DS, Zhao HH, Man CY, Steel HM, Mehta N, Peppercorn AF.
Antiviral Res. 2016 Oct;134:144-152. doi: 10.1016/j.antiviral.2016.08.023.
PMID: 27568923
Similar articles
Select item 27568922
100.
In vitro inhibition of African swine fever virus-topoisomerase II disrupts viral replication.
Freitas FB, Frouco G, Martins C, Leitão A, Ferreira F.
Antiviral Res. 2016 Oct;134:34-41. doi: 10.1016/j.antiviral.2016.08.021.
PMID: 27568922
Similar articles
